CSC Urges Enterprises Evaluate Applying for .BRAND Domains to Navigate AI-Driven Domain Threats and Opportunities

Business Wire India

CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today announced a new program to coincide with ICANN’s new Generic Top-Level Domain (gTLD) application window and to support enterprises submitting a .BRAND TLD application between April 30 and August 12, 2026.

 

Owning a .BRAND domain gives an organization exclusive control over its entire domain infrastructure, mitigating third-party lookalike domain registrations that lead to phishing and domain spoofing. This will be the first time ICANN has opened applications for new gTLDs, including .BRANDs, since the inaugural round in 2012. There is no known date for a third window opening.

 

 

As the largest provider of these domain services globally, CSC manages more than one-third (160+) of all .BRANDs, helping to secure many of the world’s most recognizable brands. Since the round one application window closed in 2012, CSC has provided continuous .BRAND registry management and operational support, ensuring uninterrupted service for existing holders. Custom .BRAND domain extensions align digital infrastructure with broader enterprise security strategies. These protections cascade automatically to every domain under the branded extension, complementing existing endpoint threat intelligence investments.

 

 

“The cyber threat landscape has escalated dramatically since the last .BRAND registration period in 2012, with AI now increasing the volume and complexity of various cyber risks ranging from automated phishing kits to domain generation algorithms,” says Gretchen Olive, vice president, Policy & Strategic Account Management, CSC Digital Brand Services. “Major global technology companies are already consolidating infrastructure services under .BRAND TLDs, citing enhanced security, privacy, and spoofing protection as primary drivers.”

 

 

During round one in 2012, CSC’s dedicated .BRAND team prepared, submitted, and supported more than 250 .BRAND applications with a 100% application evaluation success rate. ISO 27001 and SOC 2 certified, CSC offers global enterprises with complex compliance needs the ability to choose from multiple registry back-end partner systems hosted across multiple countries. This helps organizations meet industry- and country-specific requirements around security, data processing, and privacy.

 

 

“CSC supports us with the whole operational package around our three .BRANDS,” states Charlotte Falck, head of Group Trademarks and Brand Related IP. “The compliance that we have to undertake according to the ICANN program is extensive and also quite complicated if I may say so. So, we have outsourced everything to CSC, and I think it works very well.”

 

 

On top of the security benefits, .BRAND domains provide a competitive advantage for brand trust and AI-era discoverability. They eliminate the noise of third-party lookalike registrations and create an instantly recognizable, exclusively owned digital space. They also provide a structural credibility marker that signals authenticity, strengthens customer trust, and becomes a powerful source of authority for AI that traditional domains can’t match.

 

 

“AI is reshaping how buyers and stakeholders discover and evaluate brands,” says Ihab Shraim, CTO at CSC. “Success in 2026 and beyond hinges on how well an organization shows up for GEO and AEO, and a .BRAND provides a verified authority signal that both AI systems and human visitors can recognize—and trust—in real-time.”

 

 

What has changed between ICANN rounds is the strategic clarity. In 2012, many organizations applied for a .BRAND out of competitive pressure or fear of being left behind, often without a well-defined plan for how they would use it.

 

 

In this second round, AI-driven security threats and the growing role of AI in how consumers search and evaluate brands have transformed .BRAND TLDs into a practical enterprise asset. Organizations entering round two in 2026 have a clear rationale grounded in security, trust, and long-term digital strategy.

 

 

One lesson from round one: Many executives learned too late about .BRAND TLDs. CSC encourages organizations to bring this opportunity to the C-level early, so leaders can have time to assess its full strategic implications across security, brand, and digital infrastructure. Since a typical .BRAND application requires six to eight weeks of preparation, organizations need to take steps now to meet the August 12 deadline.

 

 

To prepare for ICANN’s open application window and evaluate whether a .BRAND TLD is right for your organization, schedule a free consultation with CSC’s team of specialists. For more information about CSC’s .BRAND advisory and domain security solutions and the application process, visit cscdbs.com/en/solutions/domain-portfolio-management/dot-brands/.

 

 

About CSC

 

 

CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSec℠ platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

 

 

 

 

 

Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI

Business Wire India

Boomi, the data activation company, today announced continued analyst recognition across multiple strategic technology categories, underscoring the company’s momentum as enterprises look for a unified foundation to connect data, applications, APIs, automation, and AI.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429987428/en/

 

 

Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI

Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI

 

Over the past several months, Boomi has been recognized across integration, API management, data management, and agentic AI-related categories. The company was named a Leader and positioned highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service, marking Boomi’s 12th consecutive year as a Leader. Boomi was also named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment (doc #US52034025, March 2026) and was recognized as a Challenger in the 2026 Gartner Magic Quadrant for Master Data Management Solutions, marking Boomi’s first-ever placement in that evaluation.

 

In addition, Boomi was included in the 2026 Constellation ShortList™ for Cross-Platform Agentic AI, the 2026 Constellation ShortList™ for Data Integration and Transformation for Cloud-Based Analytical Data Platforms, and the 2026 Constellation ShortList™ for Integration Platform as a Service (IPaaS). Constellation’s latest ShortLists emphasize rising enterprise demand for platforms that can orchestrate workflows across data, APIs, applications, and AI, while maintaining governance, operational control, and real-time execution.

 

 

Boomi was also named a Leader in the Nucleus Research iPaaS Technology Value Matrix 2026, marking the company’s 7th consecutive year in the Leader quadrant. Nucleus noted that iPaaS platforms are increasingly evolving into the orchestration layer for agentic workflows, with buyers now expecting support for AI workloads alongside traditional integration requirements. Boomi was also recognized as Exemplary in the ISG Buyers Guide™ for AI Agents, where ISG highlighted Boomi’s strong performance in customer experience dimensions and above-median performance in AI agent product experience areas, including APIs and integration.

 

 

Together, these recognitions reflect a broader market shift. As organizations move from AI experimentation to AI execution, they increasingly need a platform that not only connects systems and data, but also governs how APIs, automations, and AI agents operate across the enterprise. Boomi believes this momentum validates its strategy to bring integration and automation, API management, data readiness, and agent management together in a single platform.

 

 

“Enterprises have demonstrated the value of AI as well as the need to coordinate AI and data programs more effectively,” said Matt Aslett, Director of Research, Data and Analytics at ISG. “As companies move from pilots to production, the market is shifting toward platforms that can unify data, integration, governance, and orchestration so AI can operate reliably inside real business environments.”

 

 

“As enterprises race to become AI-driven, the challenge is no longer access to models, it’s whether organizations can activate trusted data, govern interactions, and orchestrate execution across increasingly complex environments,” said Steve Lucas, Chairman and CEO at Boomi. “We believe this wave of analyst recognition reflects the strength of our platform and the momentum we’re seeing from customers who want one strategic foundation for integration, APIs, data, automation, and agentic AI.”

 

 

Boomi’s recent momentum comes as the company continues to expand the Boomi Enterprise Platform to support modern, AI-driven environments. Recent innovations highlighted in Boomi’s public announcements include advances in API federation and governance, broader MCP support, data integration and managed file transfer capabilities, Agentstudio adoption, and new data-context capabilities such as Meta Hub to help ground AI agents in trusted business meaning.

 

 

Additional Resources

 

 

 

 

About Boomi

 

Boomi, the data activation company, brings data to life by integrating and governing it to power everything from AI to BI. The Boomi Enterprise Platform puts data in motion, uniting data readiness, integration and automation, and agent management in one comprehensive solution. Trusted by more than 30,000 customers and supported by a global network of 800+ partners, Boomi is driving agentic transformation — helping organizations of all sizes move faster, operate smarter, and innovate at scale. Discover more at boomi.com.

 

 

© 2026 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

 

 

Gartner, Magic Quadrant for Integration Platform as a Service, By Andrew Humphreys, Keith Guttridge, Allan Wilkins, Shrey Pasricha, 16 March 2026.

 

 

Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates.

 

 

Gartner® Magic Quadrant™ for Master Data Management, Stephen Kennedy, Lyn Robison, Divya Radhakrishnan, Dr. Usen Uboh, April 6, 2026.

 

 

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

 

 

 

 

 

Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance

Business Wire India

Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/

 

 

Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance

Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance

 

Key Financial Highlights – Q1 2026

 

  • Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY.
  • EBIT of EUR 4.6 million (4.5), +1.8% YoY.
  • EBIT margin of 27.4% (26.9%), +50 basis points YoY.
  • Foreign exchange (FX) gains EUR 1.0 million (-1.4).
  • Net income EUR 2.1 million (1.5), +36.5% YoY.
  • Free cash flow (FCF) EUR 0.2 million (1.0).
  • Earnings per share (EPS) EUR 0.1 (0.1).
  • Order book at the end of the period EUR 105.4 million (70.3), +50.0% YoY.

 

The first quarter of 2026 reflects stable revenue supported by disciplined execution across key customer programs and a strong order backlog. The company remained profitable during the period, with free cash flow reflecting temporary collection delays in certain regions amid the current geopolitical environment.

 

Revenue for the quarter was EUR 16.8 million. The revenue mix reflects the execution phase of large-scale delivery programs, particularly across MEA and APAC markets, with delivery revenues representing a higher share. The operating environment during the quarter was characterized by increased uncertainty, which impacted customer investment timing and delayed certain decision cycles.

 

 

Operating performance remained strong, with EBIT of EUR 4.6 million and an EBIT margin of 27.4%, reflecting consistent operational discipline and platform scalability. Profitability in the quarter was also supported by favorable foreign exchange movements.

 

 

Cash flow in the quarter was impacted by challenges in collections in certain regions due to the prevailing environment, leading to a buildup of receivables and an increase in Days Sales Outstanding (DSO).

 

 

Tecnotree continued to enhance its platform capabilities during the quarter, advancing its AI-enabled value chain to enhance customer experience and unlock new revenue opportunities through embedded AI across its digital BSS stack. The company also maintained its focus on increasing efficiency across internal functions and customer operations, particularly through AI-driven operations, including reporting and process automation, as well as preventive and corrective maintenance capabilities.

 

 

Padma Ravichander, CEO of Tecnotree, said:

 

 

“Our performance in the first quarter reflects the strength of our execution and the resilience of our business model. We continue to see strong demand across our markets, supported by a robust order backlog and sustained customer engagement. Our focus on AI-led innovation and operational efficiency is enabling us to deliver consistent value to our customers while strengthening our long-term growth trajectory.”

 

 

During the quarter, Tecnotree received multiple industry recognitions, including awards at the Asia Telecom Awards 2025 for AI Initiative of the Year and Digital Initiative of the Year in the MVNE/MVNO category, as well as the CX Catalyst Award for Impact at The Fast Mode Awards 2025.

 

 

The order book remained strong at EUR 105.4 million, driven by new orders in Africa and Latin America, reflecting continued demand for Tecnotree’s products and solutions. Backed by a strong backlog, disciplined execution, and continued platform innovation, the company remains well positioned for sustained growth. Management confirms that the company’s financial performance remains on track, and full-year guidance is maintained across all key metrics.

 

 

 

 

 

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN

Business Wire India

The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/

 

 

111SKIN's Reparative Collection

111SKIN’s Reparative Collection

 

Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000.

 

“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy. This investment, grounded in consumer-centricity and transformative innovation, reflects our Beauty Reimagined vision and underscores the significant opportunity we see to support the brand’s continued growth – expanding its global reach while preserving the distinctive approach that has made it so relevant with today’s consumers.”

 

 

111SKIN is a luxury clinical skin care brand, operating in a fast-growing segment where medical expertise and powerful high-performance formulations are increasingly shaping consumer demand. The brand distributes through luxury retail, e-commerce and high-end spa channels – including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman – and has a robust direct-to-consumer business representing approximately 20% of sales, reflecting strong digital engagement with prestige consumers. The brand has a diversified global footprint, with North America representing approximately 40% of 2025 sales, and an established presence across China, the United Kingdom, Europe and Asia Pacific.

 

 

“We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN,” said Dr. Yannis and Eva Alexandrides, co-founders of 111SKIN. “We look forward to building on our momentum and driving future growth together,” added CEO Vanessa Goddevrind.

 

 

Dr. Alexandrides will remain actively involved in the brand and will continue to lead 111SKIN alongside its experienced management team.

 

 

This investment aligns with The Estée Lauder Companies’ continued focus on science-driven innovation, as 111SKIN’s advanced NAC Y2™ technology and commitment to clinical-led product development reflect consumers’ growing preference for high-performance and preventative skin care.

 

 

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

 

 

ELC-C
ELC-B

 

 

 

 

 

Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea

Business Wire India

Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets.

 

The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts to help customers optimize purification processes, enhance cost and process efficiency, and advance programs toward commercial readiness.

 

 

Korea has emerged as a global center for biopharmaceutical manufacturing, particularly in biosimilars that expand access to advanced therapies worldwide. In this highly competitive environment, manufacturers require speed, technical rigor and alignment with global standards. With bioprocessing experts now based locally, customers can progress development more efficiently by avoiding overseas material transfers, while maintaining consistency and cost efficiencies across global operations.

 

 

“Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations,” said Jenny Tan, vice president and general manager, Ecolab Life Sciences APAC and India. “BPAL Korea strengthens our ability to work side by side with customers, bringing deep local expertise together with Ecolab’s global, integrated bioprocessing network.”

 

 

BPAL Korea is the latest example of Ecolab Life Sciences’ long-term investment in the life sciences industry, building on continued innovation across the company’s bioprocessing portfolio, including its affinity resin technologies. By expanding its global network of development and applications centers, Ecolab Life Sciences is helping customers drive growth and scale advanced therapies with speed, reliability, and confidence worldwide.

 

 

To learn more about Ecolab Life Sciences’ bioprocess development capabilities and how BPAL Korea supports scalable, regulatory-ready purification processes, visit Ecolab’s Purolite™ Resins website here.

 

 

About Ecolab

 

 

A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global leader in water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. For more than a century, Ecolab has advanced innovation by integrating science-based solutions, data-driven insights, AI technology and world-class service. This unique combination enables Ecolab to partner with customers to define what best-in-class looks like and scale it across their operations, helping them achieve peak performance. Today, Ecolab delivers $16 billion in annual sales, employs 48,000 associates and serves customers in more than 170 countries and 40 industries. The company helps protect one-third of the world’s food production and a quarter of the power generated while delivering innovative solutions across food, hospitality, healthcare, data centers, microelectronics and life sciences. As the world’s water company, Ecolab plays an important role in AI growth by supporting the full water needs of advanced computing—from ultra‑pure water for chip manufacturing, to water solutions that support the power behind AI, to direct liquid cooling systems for high‑density computing that improves performance while reducing environmental impact through circular water use. In life sciences, Ecolab delivers end to end solutions that support the development and manufacturing of life-saving drugs, helping customers operate safely and consistently at scale while improving performance and reducing environmental impact. Through its comprehensive approach, Ecolab protects what’s vital, with a goal by 2030 to help protect 2 billion people from infections and conserve enough drinking water for 1 billion people, while continuing to enhance business performance.

 

 

Ecolab. Protecting What’s Vital.

 

 

www.ecolab.com

 

 

Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.

 

 

(ECL-C)

 

 

 

 

 

Ion Exchange Enters Strategic Technology and Manufacturing Collaboration with MANN+HUMMEL for Advanced Membrane and System Solutions

Business Wire India

Ion Exchange (India) Ltd, a leading provider of total water and environment management solutions globally, and MANN+HUMMEL, a world leader in filtration technology and intelligent separation solutions, have announced a strategic technology transfer and manufacturing collaboration for the production of advanced PVDF Ultrafiltration (UF) membranes with integrated UltraSKID systems, and subsequently a strategic technology transfer of Membrane Bio Reactor (MBR) solutions to India.

The collaboration brings together MANN+HUMMEL Water & Membrane Solutions’ global expertise in membrane technology with Ion Exchange’s strong manufacturing capabilities, engineering strength and established presence in India’s water and wastewater treatment sector.

Under the agreement, Ion Exchange will manufacture, undertake system integration and commercialize PVDF hollow fiber ultrafiltration membranes along with integrated UltraSKID systems based on MANN+HUMMEL’s advanced technology. Production will take place at Ion Exchange’s expanded state-of-the-art HYDRAMEM® membrane manufacturing facility in Goa.

The collaboration further strengthens Ion Exchange’s HYDRAMEM® solutions to offer an integrated portfolio of membrane-based technologies, including Ultrafiltration (UF), Reverse Osmosis (RO) and Membrane Bioreactor (MBR) systems. It will enable the company to deliver globally benchmarked membrane technology manufactured locally, reduce import dependence and ensure improved supply reliability and faster delivery timelines for customers.

Sridhar Padmanaban, Senior Vice President, Ion Exchange (India) Limited, said: “This collaboration is a significant milestone in delivering world-class solutions through our advanced membrane manufacturing capabilities. It reflects our commitment to the Government’s Make in India vision and supports the larger aspiration of Viksit Bharat 2047 by advancing self-reliance in critical water treatment technologies.”

Rohit Sathe, Senior Vice President and General Manager, MANN+HUMMEL Water & Membrane Solutions, added, “This partnership with Ion Exchange reflects a strong global collaboration focused on technology transfer and localized manufacturing of advanced membrane solutions. It brings together complementary strengths to enhance the availability of high-performance filtration solutions, supporting evolving customer needs across markets.”

Nutrivita Foods Bags SME of the Year Award From Indo-French Chamber of Commerce & Industry

Business Wire India

Nutrivita Foods Pvt. Ltd., part of Groupe Nutriset of France and a leading manufacturer and exporter of therapeutic and nutritional foods was honoured with the SME of the Year 2026 award at the Indo-French Business Awards (IFBA) 2026, organized by the Indo-French Chamber of Commerce & Industry (IFCCI) and Team France Export. The award was presented by H.E. Thierry Mathou, Ambassador of France to India. Now in its 8th edition, the IFBA celebrates excellence in innovation, sustainability, leadership, and business performance among French and Indian companies operating in India.
 

Ms. Payal S. Kanwar, Director General, IFCCI said, “On behalf of the Indo-French Chamber of Commerce & Industry, I extend my warm congratulations to Nutrivita India on being recognized as SME of the Year. This achievement reflects the strength of Indo-French collaboration, where innovative solutions originating from France are successfully produced in India and contribute to global supply chains. We particularly commend the company’s continued focus on advancing formulations using locally sourced raw materials, as well as the seamless technical collaboration between French and Indian teams. This recognition is a testament to their commitment to innovation, quality, and cross-border partnership.”

Mr. Shailesh Purohit, CEO, Nutrivita Foods said, “This award reflects our continued commitment to manufacturing and delivering high-quality, innovative, and sustainable food solutions globally. This recognition underlines our partnership with Groupe Nutriset of France, whose products alone have contributed to transforming the lives of over 76 million people across the world since 2005.  Importantly, we are contributing towards achieving the United Nations Sustainable Development Goal that aims to end all forms of malnutrition by 2030 (UN-SDG 2.0: Zero Hunger). It also reinforces our dedication to contributing meaningfully to the growing collaboration between India and France.”

Nutrivita Foods blends French expertise and R&D with local sourcing in India supporting and sustaining agriculture and livelihoods in India and contributing to the Vocal for Local initiative of the Government of India.

 

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement

Business Wire India

Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/

 

 

Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities.

Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities.

 

“Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide a common settlement layer across all of them.”

 

Newly supported blockchains

 

 

Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities:

 

 

  • Arc: An open Layer-1 blockchain created by Circle, purpose-built to unite programmable money and onchain innovation with real-world economic activity.
  • Base: A high-performance blockchain enabling fast, low-cost settlement for stablecoins, onchain assets and agentic commerce. Powered by Coinbase.
  • Canton: Built with configurable privacy for regulated capital markets, enabling compliant settlement for institutional use cases.
  • Polygon: A leading blockchain payments solution that enables fast, low-cost transactions, delivering seamless, high-throughput infrastructure for global payments and digital commerce.
  • Tempo: Focused on faster, private, and more efficient movement of stablecoin liquidity and settlement flows.

 

With these additions, Visa now supports nine blockchains across its global stablecoin settlement pilot program, giving partners more choice while building on existing support for Avalanche, Ethereum, Solana, and Stellar.

 

From experimentation to multi-chain reality

 

 

Over the past year, stablecoins have evolved from a promising innovation to a practical way to move money globally, and Visa’s settlement pilots are helping partners streamline operations.

 

 

This builds on years of live pilots and regional rollouts across LAC, Europe, AP and CEMEA, as well as the recent expansion of USDC settlement to U.S. banks and 130+ stablecoin-linked card programs in more than 50 countries. The move to nine supported blockchains mirrors a broader trend: liquidity and activity now span a diverse, multi-chain ecosystem, and settlement infrastructure is evolving to match to provide more choice.

 

 

Visa is building toward a future where interoperability is essential. Supporting multiple blockchains gives partners more choice in how they access liquidity across ecosystems and adapt as the landscape changes, while Visa eases some of the underlying complexity so institutions can use stablecoins through a trusted, global network.

 

 

Continued momentum

 

 

The growth to a $7B run rate underscores increasing confidence in blockchain infrastructure from financial institutions, fintechs, and payment providers. Stablecoin settlement over blockchain infrastructure is becoming a viable complement to traditional settlement rails.

 

 

As adoption continues, Visa remains focused on bridging traditional finance and blockchain-based systems – bringing the same standards of reliability, security, and scale to both.

 

 

Partner perspectives

 

 

“Arc is designed to provide the performance, predictability, and reliable access to liquidity needed to support real-time settlement at a global scale. Our work with Visa reflects growing demand for stablecoins like USDC and blockchain infrastructure that can settle today’s payment flows instantly while enabling the next era of programmable commerce and agent-driven economic activity.” Nikhil Chandhok, Chief Product and Technology Officer, Circle.

 

 

“Our goal with Base has always been to make onchain the new standard. Visa’s expansion is a pivotal step in making stablecoin payments a daily reality for billions of people, enabling a faster, cheaper, and more useful financial system for everyone,” said Jesse Pollak, Founder of Base.

 

 

“Canton was designed to meet demanding requirements of regulated institutions, and Visa’s stablecoin settlement platform provides a bridge that lets them explore onchain settlement while staying aligned with their compliance requirements,” said Eric Saraniecki, Head of Network Strategy at Digital Asset, co-founder of the Canton Network.

 

 

“Visa adding Polygon signals that stablecoins are moving into real world payments at scale. By combining Visa’s global reach with Polygon’s fast, low-cost infrastructure, we are making stablecoin settlement more practical, reliable, and accessible for partners around the world,” said Marc Boiron, CEO, Polygon Labs.

 

 

“Tempo is focused on real-time stablecoin settlement, and Visa’s participation as both a validator and settlement partner helps bring always-on, programmable payments closer to the mainstream,” said Ani Narayan, GTM, Tempo.

 

 

About Visa

 

 

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

 

 

 

 

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

Business Wire India

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease

Results from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma

 

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication.

 

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said:

 

 

“HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Priority Review designation is a major milestone in our effort to bring better first‑line options to patients with HER2‑positive gastroesophageal adenocarcinoma. We will work in partnership with regulators to support the review process, with the aim of rapidly bringing this new treatment option to patients.”

 

 

Data supporting sBLA filing

 

 

The sBLA submission is based on the first interim analysis (IA1) of HERIZON-GEA-01, a global Phase 3 clinical trial designed to evaluate ZIIHERA plus chemotherapy, with and without TEVIMBRA, compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ GEA. Key findings of the trial include:

 

 

  • Overall survival (OS): The arm in which TEVIMBRA was added to ZIIHERA and chemotherapy resulted in a statistically significant improvement in OS (median OS of 26.4 months) at IA1. The ZIIHERA plus chemotherapy arm achieved a median OS of 24.4 months and the control arm resulted in a median OS of 19.2 months.
  • Progression-free survival (PFS): Both ZIIHERA-containing arms delivered a statistically significant and clinically meaningful improvement in median PFS of 12.4 months compared with 8.1 months in the control arm.
  • Improvement in OS and PFS was observed regardless of PD-L1 status.
  • The safety findings for the ZIIHERA plus TEVIMBRA and chemotherapy arm were generally consistent with the known effects of the components of the combination regimen, and no new safety signals were identified.

 

Project Orbis pathway

 

BeOne plans to participate in the FDA’s Project Orbis, an initiative that provides a framework for collaborative review of oncology products among international partners, for the submission of the HERIZON-GEA-01 data in territories in which BeOne holds the ZIIHERA license. With this pathway, BeOne aims to accelerate approval and patient access to this treatment, recognizing the global significance of the HERIZON‑GEA‑01 results, which demonstrated meaningful survival improvements in a disease where outcomes have remained largely unchanged for more than a decade.

 

 

About the HERIZON-GEA-01 Phase 3 Trial

 

 

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with Jazz Pharmaceuticals, to evaluate and compare the efficacy and safety of ZIIHERAplus chemotherapy, with and without TEVIMBRA, to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries. Patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: ZIIHERAin combination with chemotherapy and TEVIMBRA; ZIIHERA in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial is evaluating dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

 

 

About Gastroesophageal Adenocarcinoma

 

 

Gastroesophageal adenocarcinoma (GEA), which includes cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide. Approximately 20% of GEA patients have HER2-positive disease1,2,3, which has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 30% for gastric cancer and about 19% for GEA.4

 

 

About ZIIHERA (zanidatamab)

 

 

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.5

 

 

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

 

 

ZIIHERA is a registered trademark of Zymeworks BC Inc.

 

 

About TEVIMBRA (tislelizumab)

 

 

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

 

 

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes more than 15,000 patients enrolled to date in 30+ countries and regions across 72 trials, including 22 registration-enabling studies. TEVIMBRA is approved in 50 countries, and more than 1.9 million patients have been treated globally.

 

 

Select Important Safety Information

 

 

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

 

 

Please see fullU.S. Prescribing Informationincluding theU.S. Medication Guide.

 

 

The information in this press release is intended for a global audience. Product indications vary by region.

 

 

About BeOne

 

 

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement

 

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of ZIIHERA and TEVIMBRA; the potential of TEVIMBRA plus ZIIHERA and chemotherapy to shift the treatment paradigm in first-line HER2-positive metastatic GEA; the potential opportunity to expand access; BeOne’s expectations regarding ZIIHERA’s and TEVIMBRA’s clinical development and regulatory milestones; BeOne’s plans to submit the data for publication; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit ourNewsroomsite.

 

 

____________________

1 Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.

2 Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.

3 Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.

4 Battaglin F, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International. 2018;18(99).

5 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.

 

 

 

 

 

 

Savings Account vs Current Account: Key Differences Explained

Business Wire India

The two common bank account categories in India are savings accounts and current accounts. Both fulfil the need to store and manage finances with ease but serve different types of account holders.

 

One is meant for personal banking, and the other helps businesses. As a result, the functioning is vastly different for both accounts. Learn everything you need to know about the distinction between a savings account and a current account in this detailed blog.

 

What is a savings account

 

A savings account serves as a safe place to park your money and earn interest on your balance based on the savings account interest rate. It is ideal for managing your salary or setting aside funds for short-term goals.

 

The main appeal of a savings account is building a habit of saving regularly and growing funds steadily. You can also benefit from the digital tools for money management and swift transactions.

 

What is a current account

 

A current account is designed for businesses and professionals who deal with frequent transactions. You can send and receive large amounts with higher transaction limits.

 

Unlike a savings account, the focus is on the flexibility and specialised business-specific features like overdraft facility, cash flow management solutions, and the like. Hence, a current account does not earn interest.

 

Savings account vs current account: Key differences

 

As savings and current accounts are built for different money management needs, they are distinct in terms of:

 

Factors

Savings account

Current account

Use case

Storing regular savings or salary and making bill payments, peer transfers, and other regular transactions

Designed for businesses and professionals to manage frequent and high-volume transactions

Interest earnings

Earns interest based on the savings account interest rate and grows balance over time

Typically, does not earn interest on balance

Minimum balance requirement

Lower and easier to maintain. Some accounts come with zero balance requirement

Higher and varies based on the bank and type of current account

Transaction limit

Limited transactions per month as per bank rules

Higher or unlimited transaction limits

Fees and charges

Usually minimal for most banking services

Potentially higher charges for non-maintenance and additional services

Suitable for

Individuals looking to save and manage money steadily

Businesses, contract workers, and professionals dealing with frequent cash flow

Credit line

Rarely includes access to credit line as an account feature

Often includes overdraft facility to fund short-term needs

 

Distinct benefits of a savings account vs a current account

 

Beyond the basic differences, both bank accounts offer diverse advantages that shape your banking journey. Here’s how the distinct benefits play out:

 

Benefits of a savings account:

 

  • Steady growth of funds: Your account balance grows over time as the savings account interest rate applies.

  • Promotes disciplined saving: You can save for small or big financial goals regularly due to the flexibility of making deposits.

  • Low maintenance pressure: Most savings accounts have simpler requirements with minimal account balance requirements, which makes it easier to maintain.

  • Seamless digital management: Almost all banking services are accessible through the net or mobile banking, including online account opening. This limits the need for bank visits.

  • Enhanced security: Up to Rs 5 lakh of your savings deposits are insured with the DICGC. IDFC Bank also enable advanced encryption and two-factor authentication for secure transactions.

 

Benefits of a current account:

 

  • Ideal for frequent, high-volume transactions: Easily manages the continuous inflow and outflow of transactions without restrictions.

  • Helps with record-keeping: With real-time updates and detailed transaction history through banking apps, you can easily track all business transactions.

  • Easy access to credit: You can meet your working capital and short-term cash needs through an overdraft facility.

  • Better financial organisation: You can separate business finances and make your day-to-day money management more structured.

  • Multiple payment options: You can transact in multiple ways, using cheques, debit/credit cards, and digital banking solutions to account for diverse payment needs.

 

Based on the differences discussed above, the ease of money management remains similar with a savings account and a current account. The distinction comes down to different financial journeys.

 

Once you’ve settled on the account type that works best for you, the setup process is simple with IDFC Bank’s online bank account opening. You can get started with minimal documentation from the comfort of your home.

 

Insights and content strategy for this article were supported by Teamology.